Deanna Padgett
Psychiatric/Mental Health · Texarkana, TXNPI 1285148585
Payments from drug & device makers
Across 606 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- AbbVie$1K
- plus $2K from 10 others
What the payments were for
- Food & beverage$10,10899%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 103 | $1,674 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,375 |
| Neurocrine Biosciences, Inc. | 51 | $1,284 |
| Alkermes, Inc. | 74 | $1,277 |
| Vanda Pharmaceuticals Inc. | 49 | $1,105 |
| AbbVie | 144 | $1,066 |
| Teva Pharmaceuticals USA, Inc. | 40 | $777 |
| Indivior Inc. | 25 | $474 |
| Johnson & Johnson | 16 | $413 |
| E.r. Squibb & Sons, L.L.C. | 17 | $306 |
| Sunovion Pharmaceuticals Inc. | 16 | $285 |
| Novo Nordisk | 1 | $74 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$875
- INGREZZA$221
- CAPLYTA$108
- Austedo XR$105
How this compares
$10,238 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 44 | $296,774 |
| Austedo XrDeutetrabenazine | 29 | $187,775 |
| Invega SustennaPaliperidone Palmitate | 65 | $177,357 |
| VraylarCariprazine Hcl | 90 | $131,300 |
| IngrezzaValbenazine Tosylate | 13 | $114,547 |
| CaplytaLumateperone Tosylate | 44 | $79,790 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $57,640 |
| AristadaAripiprazole Lauroxil | 13 | $45,303 |
| RexultiBrexpiprazole | 24 | $40,660 |
| UzedyRisperidone | 12 | $33,672 |
| Lurasidone Hcl | 40 | $25,992 |
| FanaptIloperidone | 17 | $16,187 |
| Aripiprazole | 123 | $12,640 |
| StratteraAtomoxetine Hcl | 27 | $12,483 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $413 | $474,130109 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $777 | $221,44641 claims |
| AbbVieVraylar | $1,066 | $131,30090 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,284 | $114,54713 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,277 | $102,94241 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,674 | $79,79044 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,375 | $40,66024 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,105 | $16,18717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Texarkana
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.